Gilead's Descovy HIV Prevention Indication Should Exclude Women, US FDA Advisory Cmte. Says

Gilead and the FDA failed women by letting PrEP application get this far without clinical efficacy data in non-transgendered females, panel members say in close vote against a broad indication; panelists urge the agency to mandate such studies regardless of the breadth of the HIV pre-exposure prophylaxis indication ultimately granted to the Truvada successor.

FDA Advisory Committee Feature image
An FDA AdComm majority supported a narrow PrEP indication for Descovy.

A divided US Food and Drug Administration advisory committee on 7 August narrowly recommended against including cisgender women in an HIV pre-exposure prophylaxis indication for Gilead Sciences Inc.’s Descovy (emtricitabine/tenofovir alafenamide) due to the lack of clinical efficacy data.

Despite the 10-8 vote against a broad PrEP indication, the committee members were strongly united on one point: the FDA...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers